$0.88
3.17%
Downside
Day's Volatility :4.49%
Upside
1.37%
14.77%
Downside
52 Weeks Volatility :42.31%
Upside
32.31%
Period | Chimerix Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.16% | 5.1% | 0.0% |
6 Months | -30.48% | 4.9% | 0.0% |
1 Year | -16.57% | 16.6% | 0.0% |
3 Years | -87.45% | 13.2% | -22.3% |
Market Capitalization | 79.7M |
Book Value | $1.74 |
Earnings Per Share (EPS) | -0.96 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.83 |
Profit Margin | 0.0% |
Operating Margin TTM | -17699.23% |
Return On Assets TTM | -28.22% |
Return On Equity TTM | -44.62% |
Revenue TTM | 144.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 396.20000000000005% |
Gross Profit TTM | -36.5M |
EBITDA | -94.6M |
Diluted Eps TTM | -0.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.88 |
EPS Estimate Next Year | -1.0 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.24 |
What analysts predicted
Upside of 676.14%
Sell
Neutral
Buy
Chimerix Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Chimerix Inc | 4.66% | -30.48% | -16.57% | -87.45% | -57.68% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Chimerix Inc | 0.48 | NA | 0.0 | -0.88 | -0.45 | -0.28 | NA | 1.74 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Chimerix Inc | Buy | $79.7M | -57.68% | 0.48 | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Chimerix Inc
Revenue is up for the last 2 quarters, 4.0K → 129.0K (in $), with an average increase of 96.9% per quarter
Netprofit is up for the last 2 quarters, -21.86M → -20.68M (in $), with an average increase of 5.7% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 53.7%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 156.6%
RA Capital Management, LLC
Monaco Asset Management
Vanguard Group Inc
Armistice Capital, LLC
Acadian Asset Management LLC
Renaissance Technologies Corp
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Organization | Chimerix Inc |
Employees | 72 |
CEO | Mr. Michael T. Andriole M.B.A. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.88
-0.35%
Keyarch Acquisition Corp
$0.88
-0.35%
Connexa Sports Technologies Inc
$0.88
-0.35%
Us Value Etf
$0.88
-0.35%
First Wave Biopharma Inc
$0.88
-0.35%
Global X Msci Next Emerging
$0.88
-0.35%
Fat Projects Acquisition Corp
$0.88
-0.35%
Capital Link Global Fintech
$0.88
-0.35%
Applied Uv Inc
$0.88
-0.35%